Journal of Clinical and Aesthetic Dermatology

FEB 2018

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link:

Contents of this Issue


Page 61 of 62

59 JCAD JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY February 2018 • Volume 11 • Number 2 R E V I E W as first-line treatments for melasma in either sex. Their use should be restricted to cases unresponsive to topical therapy or chemical peels. CONCLUSION Melasma has traditionally been considered to be a pigmentation disorder of the female sex, but the occurrence in men is not uncommon. It appears to affect dark-skinned men of Asian and African- American origin more frequently than previously thought. Melasma has a multifactorial origin that is exacerbated by environmental factors such as sunlight, especially in those genetically predisposed to the condition. The etiopathogenesis of melasma in men is similar to that of women, except for hormonal factors, which are more prevalent in women. The role of mustard oil needs to be better substantiated. Malar melasma is most common in men. The treatment of melasma is challenging, often unsatisfactory, and needs to be continued indefinitely to avoid recurrence. To ensure optimal adherence, clinicians should consider individual patient needs, preferences, and expectations when devising a treatment plan. Strict sun protection, including sunscreens, do offer some protection against relapse, but it is not guaranteed. Further studies on melasma in men belonging to different population groups would go a long way in a better understanding of the differences from their female counterparts. REFERENCES 1. Pandya AG, Guevara IL. Disorders of hyperpigmentation. Dermatol Clin. 2000;18:91–8. 2. Grimes PE. Melasma: etiological and therapeutic considerations. Arch Dermatol. 1995;131:1453–1457. 3. Al-Hamdi KI, Hasony HJ, Jareh HL. Melasma in Basrah: A clinical and epidemiological study. MJBU. 2008;26:1–5. 4. Taylor SC. Epidemiology of skin diseases in people of color. Cutis. 2003; 71:271–275. 5. Sarkar R, Puri P, Jain RK, et al. Melasma in men: a clinical, aetiological and histological study. J Eur Acad Dermatol Venereol. 2010;24: 768–772. 6. Pichardo R, Vallejos Q, Feldman SR, et al. The prevalence of melasma and its association with quality of life in adult male Latino migrant workers. Int J Dermatol. 2009;48: 22–26. 7. Hiletework M. Skin diseases seen in Kazanchis health center. Ethiop Med J. 1998;36:245–254. 8. Parthasaradhi A, Al Gufai AF. The pattern of skin disease in Hail region, Saudi Arabia. Ann Saudi Med. 1998;18:558–561. 9. Tomb RR, Nassar JS. Profile of skin diseases observed in a department of dermatology (1995–2000). J Med Liban. 2000;48:302–309. 10. Werlinger KD, Guevara IL, Gonzalez CM, et al. Prevalence of self-diagnosed melasma among pre-menopausal Latino women in Dallas and Forth Worth, Tex. Arch Dermatol. 2007;143:424–425. 11. Walker SL, Shah M, Hubbard VG, et al. Skin disease is common in rural Nepal: results of a point prevalence study. Br J Dermatol. 2008;158:334–338. 12. Wang R, Wang T, Cao L et al. Prevalence of melasma in Chinese Han and Chinese Yi: a survey in Liangshan district. Chin J Dermatovenereol. 2010;24:546–548. 13. Achar A, Rathi SK. Melasma: a clinico-epidemiological study of 312 cases. Indian J Dermatol. 2011;56:380–382. 14. Hexsel D, Lacerda DA, Cavalcante AS, et al. Epidemiology of melasma in Brazilian patients: a multicenter study. Int J Dermatol. 2013;53:440–444. 15. Goh CL, Dlova CN. A retrospective study on the clinical presentation and treatment outcome of melasma in a tertiary dermatological referral centre in Singapore. Singapore Med J. 1999;40:455–458. 16. Vazquez M, Maldonado H, Benmaman C, et al. Melasma in men. a clinical and histologic study. Int J Dermatol. 1988;27:25–27. 17. Sarkar R, Jain RK, Puri P. Melasma in Indian males. Dermatol Surg. 2003;29: 204. 18. Ortonne JP, Arellano I, Berneburg M, et al. A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma. J Eur Acad Dermatol Venereol. 2009;23:1254–1262. 19. Tamega AA, Miot LD, Bonfietti C, et al. Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women. J Eur Acad Dermatol Venereol. 2013;27:151–156. 20. Hughes BR. Melasma occurring in twin sisters. J Am Acad Dermatol. 1987;17:841. 21. Sheth VM, Pandya AG. Melasma: a comprehensive update: part I. J Am Acad Dermatol. 2011;65:689–697. 22. Moin A, Jabery Z, Fallah N. Prevalence and awareness of melasma during pregnancy. Int J Dermatol. 2006;45: 285–288. 23. Tamega Ade A, Miot LD, Bonfietti C, Gige TC, Marques ME, Miot HA. Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women. J Eur Acad Dermatol Venereol. 2013;27:151–156. 24. Goh CL, Dlova CN. A retrospective study on the clinical presentation and treatment outcome of melasma in a tertiary dermatological referral centre in Singapore. Singapore Med J. 1999;40:455–458. 25. Keeling J, Cardona L, Benitez A et al. Mequinol 2%⁄ tretinoin 0.01% topical solution for the treatment of melasma in men: a case series and review of the literature. Cutis. 2008;81:179–183. 26. Guinot C, Cheffai S, Latreille J, et al. Aggravating factors for melasma: a prospective study in 197 Tunisian patients. J Eur Acad Dermatol Venereol. 2010;24: 1060–1069. 27. Videira IF, Moura DF, Magina S. Mechanisms regulating melanogenesis. An Bras Dermatol. 2013;88:76–83. 28. Mahmoud BH, Ruvolo E, Hexsel CL, et al. Impact of long- wavelength UVA and visible light on melanocompetent skin. J Invest Dermatol. 2010;130:2092–2097. 29. Perez M, Sanchez JL, Aquilo F. Endocrinologic profile of patients with idiopathic melasma. J Invest Dermatol. 1983; 81: 543–545. 30. Sialy R, Massan I, Kaur I, et al. Melasma in men: a hormonal profile. J Dermatol. 2000; 27: 64–65 31. Mahmood K, Nadeem M, Aman S, et al. Role of estrogen, progesterone and prolactin in the etiopathogenesis of melasma in females. J Pak Assoc Dermatol. 2011;21: 241–47. 32. Tadokoro T, Rouzaud F, Itami S, et al. The inhibitory effect of androgen and sex-hormone-binding globulin on the intracellular cAMP level and tyrosinase activity of normal human melanocytes. Pigment Cell Res. 2003;16:190–219. 33. Ogita A, Funasaka Y, Ansai S, Kawana S, Saeki H. Melasma in a male patient due to estrogen therapy for prostate cancer. Ann Dermatol. 2015;27:763–764. 34. O'Brien TJ, Dyall-Smith D, Hall AP. Melasma of the forearms. Australas J Dermatol. 1997;38:35–37. 35. Burkhart CG. Chloasma in a man due to oral hormone replacement. Skinmed. 2006;5:46–47. 36. Famenini S, Gharavi NM, Beynet DP. Finasteride associated melasma in a Caucasian male. J Drugs Dermatol. 2014;13:484–486. 37. Ghunawat S, Sarkar R, Garg VK. Imatinib induced melasma-like pigmentation: Report of five cases and review of literature. Indian J Dermatol Venereol Leprol. 2016;82:409–412. 38. Rostami M, Iranparvar M, Maleki N, et al. Evaluation of autoimmune thyroid disease in melasma. J Cosmet Dermatol. 2015;14:167–171. 39. Muller I, Rees DA. Melasma and endocrine disorders. Pigmentary Disorders. 2014;S1:001. 40. Ritter CG, Fiss DV, Borges da Costa JA, de Carvalho RR, Bauermann G, Cestari TF. Extra-facial melasma: clinical, histopathological, and immunohistochemical casecontrol study. J Eur Acad Dermatol Venereol. 2013;27: 1088–271094. 41. Madke B, Kar S, Yadav N et al. Extrafacial melasma over forearms. Indian Dermatol Online J. 2016;7:344–345. 42. Lonsdale-Eccles AA, Langtry JA. Melasma on the nape of the neck in a man. Acta Derm Venereol. 2005;85: 181–182. 43. Jang YH, Sim JH, Kang HY, et al. The histopathologic characteristics in male melasma: comparison with female melasma and lentigo. J Am Acad Dermatol. 2012; 66: 642–649. 44. Kang HY, Hwang JS, Lee JY et al. The dermal stem cell factor and c-kit are overexpressed in melasma. Br J Dermatol. 2006; 154: 1094–1099. 45. Ikino JK, Nunes DH, Silva VPMD, et al. Melasma and assessment of the quality of life in Brazilian women. An Bras Dermatol. 2015;90:196–200. 46. Yalamanchili R, Shastry V, Betkur J. Clinico-epidemiological study and quality of life assessment in melasma. Indian J Dermatol. 2015;60:519. 47. Rendon MI, Benitez AL, Gaviria JI. Telangiectatic melasma: a new entity? J Cosmet Dermatol. 2007;20(1):17–21 48. Manjunath KG, Kiran C, Sonakshi S et al. Melasma: through the eye of a dermoscope. Int J Res Dermatol. 2016;2:113–117. 49. Sarkar R, Arora P, Garg VK, Sonthalia S, Gokhale N. Melasma update. Indian Dermatol Online J. 2014;5: 426–435 50. Krupashankar DS, Godse K, Aurangabadkar S, et al. Evidence-based treatment for melasma: expert opinion and a review. Dermatol Ther (Heidelb). 2014; 4(2):165–186. 51. Buller DB, Anderson PA, Walkosz BJ, et al. Compliance with sunscreen advice in a survey of adults engaged in outdoor winter recreation at high-elevation ski areas. J Am Acad Dermatol. 2012; 66: 63–70. 52. Salam A, Dadzie OE,Galadari H. Chemical peeling in ethnic skin: an update. Br J Dermatol 2013;169(Suppl. 3):82–90. 53. Arora P, Sarkar R, Garg VK, et al. Lasers for treatment of melasma and post-inflammatory hyperpigmentation. J Cutan Aesthet Surg. 2012;5: 93–103. 54. Sheth VM, Pandya AG. Melasma: a comprehensive update part II. J Am Acad Dermatol. 2011; 65: 699–714. JCAD

Articles in this issue

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - FEB 2018